Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma: A systematic review and meta‑analysis

作者：Xiaoyang Yang, Mengjie Wan, Yu Feng, Zhidong Wang · 发表于：Experimental and Therapeutic Medicine · 年份：2019 · DOI：10.3892/etm.2019.7691 · 被引用次数：24 · 研究领域：Hematopoietic Stem Cell Transplantation、Multiple Myeloma Research and Treatments、Neutropenia and Cancer Infections

Plerixafor in combination granulocyte‑colony stimulating factor (G‑CSF) has been used for the mobilization of hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non‑Hodgkin lymphoma (NHL) and multiple myeloma (MM). The aim of this study was to systematically search the published literature and analyze evidence on the efficacy of additional plerixafor for successful HSC mobilization in patients with NHL and MM, and to evaluate the safety of the drug. The PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and Google scholar databases were searched electronically for studies published in the English language up to March, 2019. Five studies (3 on NHL and 2 on MM) were included in this review article. The meta‑analysis of data of 364 patients in the treatment group and 368 patients in the control group, indicated that the mobilization of ≥5/6x106 CD34+ cells/kg in 4 or less apheresis days was superior with plerixafor + G‑CSF than with G‑CSF alone (RR=2.59, 95% CI: 1.40 to 4.81; P<0.0001). Similarly, a greater proportion of patients in the treatment group exhibited the mobilization of ≥2x106 CD34+ cells/kg in 4 or less apheresis days (RR=1.46, 95% CI: 1.01 to 2.12; P=0.04). The addition of plerixafor significantly increased the total collection of CD34+ cells (random: MD=4.21; 95% CI: 2.85 to 5.57; P<0.00001). Meta‑analysis indicated no significant increase in adverse events with th...